Citius Pharmaceuticals, Inc. — FY2023 Form 10-K
Business and reporting period. This annual report covers the fiscal year ended September 30, 2023 (not calendar Q4 alone). Citius is a development-stage biopharmaceutical company with no product revenue to date. Its principal programs are LYMPHIR, Mino-Lok, Halo-Lido and NoveCite; the company terminated its Mino-Wrap license in December 2023.
Financial performance and liquidity
| Metric | FY2023 | FY2022 |
|---|---|---|
| Revenue | $0 | $0 |
| Research and development expense | $14.8 million | $17.7 million |
| General and administrative expense | $15.3 million | $11.8 million |
| Stock-based compensation expense | $6.6 million | $3.9 million |
| Operating loss | $36.7 million | $33.3 million |
| Net loss | $32.5 million | $33.6 million |
| Net cash used in operating activities | $29.1 million | $28.4 million |
- FY2023 other income included $1.2 million of interest income and a one-time $3.6 million gain from selling New Jersey tax net operating losses. The gain helped reduce the reported net loss; it is not product revenue.
- Loss per share applicable to common stockholders was $0.22 versus $0.23 in FY2022. FY2023 included a $1.15 million deemed dividend related to extending certain warrants.
- Cash and cash equivalents were $26.5 million at September 30, 2023, down from $41.7 million a year earlier. Working capital was approximately $29 million; total assets were $103.6 million and total liabilities $12.2 million. No interest-bearing debt is shown on the balance sheet; liabilities include lease obligations, payables, accruals and deferred taxes.
- Stockholders’ equity was $90.8 million, with an accumulated deficit of $162.2 million. Gross margin is not meaningful because the company had no revenue.
Changes, developments and outlook
- Net loss narrowed by $1.1 million, but operating loss increased by $3.4 million. Lower R&D costs—mainly for LYMPHIR and NoveCite—were offset by higher G&A and stock-based compensation. The tax-loss sale and higher interest income boosted other income.
- LYMPHIR: The FDA issued a complete response letter in July 2023 requiring enhanced product testing and additional controls; it cited no concerns with the clinical safety or efficacy package and requested no additional clinical trials for resubmission. Management planned to resubmit the BLA in early 2024. Approval and launch remain uncertain. The company estimated an addressable U.S. market exceeding $400 million, an internal estimate rather than realized demand.
- Mino-Lok: The Phase 3 trial reached its required 92 catheter-failure events in August 2023. Enrollment was declared complete in late December 2023, with site shutdown activities to follow; topline results were anticipated in the first half of 2024.
- Halo-Lido: The company reported positive Phase 2b results in June 2023. At the end of seven days, 42% of patients in the high-dose combination group reached the meaningful-change threshold, versus 29% for high-dose halobetasol and 21% for lidocaine. The filing says the company planned an end-of-Phase-2 FDA meeting; further development and regulatory requirements remain open.
- Business Combination: In October 2023, Citius and Citius Oncology agreed to a proposed merger with TenX. At closing, Citius Pharma was to receive 67.5 million shares of the combined company and contribute $10 million cash. Completion was expected in the first half of 2024, subject to approvals and other conditions; there is no assurance it will close.
- Management estimated available cash would fund operations through August 2024 and expected to seek additional capital in 2024. The auditor’s report and filing identify substantial doubt about the company’s ability to continue as a going concern. Management’s plans depend on financing, regulatory outcomes and product revenues, none assured.
- Nasdaq notified the company in September 2023 that its share price had been below $1 for 30 consecutive business days; the stated compliance deadline was March 11, 2024. The May 2023 equity offering raised approximately $13.8 million net and included warrants, adding potential dilution.
Key risks and unusual items
- The company has recurring losses, no operating revenue, substantial cash burn and a finite stated cash runway; continued operations require additional funding or successful commercialization.
- Regulatory, clinical, manufacturing, reimbursement and market-acceptance risks are material. The company relies on third parties for clinical trials and manufacturing and has no established commercial track record.
- LYMPHIR carries substantial potential milestone and royalty obligations to Eisai and Dr. Reddy’s if approved and commercialized. The proposed merger also entails a $10 million cash contribution and may not close.
- Potential share dilution includes outstanding warrants and options; the filing reports 50.9 million warrant shares and 13.3 million option shares outstanding at September 30, 2023. The company has not paid dividends and does not expect to do so in the foreseeable future.
- The filing reports no material pending litigation and no off-balance-sheet arrangements. Management concluded disclosure controls and internal control over financial reporting were effective as of September 30, 2023.
Important facts for investors to verify
- Whether the LYMPHIR BLA was resubmitted, accepted for review and ultimately approved, and what costs or additional FDA requirements arose.
- Mino-Lok’s Phase 3 topline results, statistical significance, safety profile and subsequent regulatory plan.
- Actual cash burn, financing raised after September 30, 2023, and whether the company’s runway extended beyond the stated August 2024 estimate.
- Status and final terms of the TenX Business Combination, including closing conditions, the $10 million contribution, share distribution plans and potential tax consequences.
- Nasdaq bid-price compliance and the effect of outstanding warrants, options and future financing on dilution.
- Whether Halo-Lido’s Phase 2b findings support a viable FDA-agreed development path and whether Mino-Wrap’s license termination resulted in any further obligations.